H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

May 14, 2026 6:48 AM

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found